Retina specialists Baruch D. Kuppermann, MD, PhD, and Firas M. Rahhal, MD, discuss the significance of bevacizumab-vikg's ...
The most meaningful part is not technological. It is personal. Vision-threatening diseases create uncertainty and fear. Home ...
In this Q&A, Vance Thompson, MD, clears up myths about dry eye and LASIK wearing off, and explains how better screening and ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
Three cases illustrate treatment switches and extension intervals across retinal vein occlusion, age-related macular degeneration, and diabetic retinopathy.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s ...
Gulani, MD, introduces the Gulani classification of refractive lens exchange, a 4-type framework for individualizing premium ...
Jordana Fein, MD, MS, presented 64-week QUASAR data showing aflibercept 8 mg sustained visual acuity gains with up to 3 fewer injections than aflibercept 2 mg in macular edema following RVO.
Real-world Spectrum data show aflibercept 8 mg boosts early vision and retinal anatomy in wet AMD, including switch patients. Welcome back to another Ophthalmology Times Europe Rapid Readout. In this ...
Real-world SPECTRUM data shows strong fluid resolution and vision gains by week 12, with low adverse events and no retinal vasculitis. Welcome back to another Ophthalmology Times Europe Rapid Readout.
New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
Not every patient with geographic atrophy (GA) fits neatly into the criteria used in the pivotal clinical trials that led to the FDA approval of pegcetacoplan and avacincaptad pegol. That gap shaped a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results